We are live on ! Find out more
RLMD icon

Relmada Therapeutics
RLMD

Fund managers haven’t disclosed any holdings of RLMD yet.

RLMD Hedge Fund Activity: Q1 2026 in Review

103 of the 8,126 institutional investors tracked by Wall St. Rank reported a position in Relmada Therapeutics (RLMD) for Q1 2026, worth a combined $589M — up 136% from $249M a quarter earlier.

Buyers outnumbered sellers: 37 funds opened new RLMD positions and 10 closed out — a net gain of 27 holders — while 27 added to existing stakes and 25 trimmed.

The largest buyer was VR Adviser, opening a new position worth an estimated $22.9M. The largest seller was Braidwell, exiting entirely with an estimated $7.64M sold.

  • 103 institutional investors held Relmada Therapeutics (RLMD) as of Q1 2026, up from 78 in Q4 2025.
  • Funds reported $589M of Relmada Therapeutics stock for Q1 2026, up 136% quarter-over-quarter.
  • 37 funds opened new Relmada Therapeutics positions in Q1 2026 and 10 closed out, a net change of +27 holders.
  • The largest Relmada Therapeutics buyer in Q1 2026 was VR Adviser, an estimated $22.9M added.
  • The largest Relmada Therapeutics seller in Q1 2026 was Braidwell, an estimated $7.64M sold.

Based on aggregated 13F filings for Q1 2026.